PureTech Health plc announced that to oversee the LYT-100 development program in IPF, Paul Ford, M.D., Ph.D., has joined PureTech as SVP of Clinical Development. He has built and advanced programs from early to late-stage development at companies including Novartis, Galapagos and Galecto, and he has driven the recruitment and randomization of nearly 1,500 patients with IPF across several clinical studies.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
233 GBX | +0.65% | +2.19% | +20.24% |
05-29 | PureTech's Ankili to be acquired by Virtual Therapeutics | AN |
05-29 | PureTech Health's Akili, Virtual Therapeutics Sign Merger Deal to Launch Digital Health Company | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.24% | 802M | |
+46.19% | 55.7B | |
+39.98% | 39.91B | |
-6.14% | 39.57B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
+28.38% | 12.17B | |
+24.18% | 12.12B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- PRTC Stock
- News PureTech Health plc
- PureTech Health plc Appoints Paul Ford as SVP of Clinical Development